Scroll To Top
Search by Speciality


Paris Marriott Rive Gauche Hotel & Conference Center # | Paris, FRANCE
From 630 to 1080 EUR
Event Preview
This event
is Finished
Specialty: Radiation Oncology
Dates: From Mar, 6, 2017 to Mar, 8, 2017
Location: Paris, FRANCE
Type: Congress
Registration Cost: From 630 to 1080 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Paris, France.
General Info
Event Venue:

Paris Marriott Rive Gauche Hotel & Conference Center #

Situated in downtown with direct access to major airports and considered one of the premium four-star hotels in Paris, Paris Marriott Rive Gauche Hotel & Conference Center is conveniently located by the Latin Quarter and Saint-Germain-des-Pres. The metro station nearby takes you directly to the Eiffel Tower, Champs Elysees, Montparnasse business district and Notre Dame in less than half an hour. All guest rooms are larger than the average 4-star Paris hotel room. Our four-star Paris hotel features spectacular views, comfortable Revive bedding and upscale shower products. The 70s-inspired R'Yves Great Room concept combines a restaurant, cocktail bar and private lounges as well as a take-away counter for guests to enjoy great food in a trendy atmosphere with wireless Internet. In the central Rive Gauche vicinity of France's capital city, we provide excellent services and facilities for a successful business trip, weekend visit or a holiday away in this unique European destination.  

Business Meetings & Services

  • Our business hotel near Montparnasse offers easy access to the congress center and nearby airports.
  • Experience Paris’ largest business hotel, with 50 event rooms and 4,800 square meters of space.
  • We easily accommodate meeting delegates with our 757 hotel rooms and suites for overnight stays.
  • Ideal for Paris business travel, we can host up to 1,200 delegates in 40 smaller breakout rooms.
  • The culinary team at our business hotel caters for meetings, conferences and exhibitions near Bercy.
  • Click here to download our MeetingMatrix® Certified Diagrams to start planning your next event.  
Visit the Venue to read more
Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

Why attend the TAT Congress series that focuses on phase 1 trials in oncology? There are several reasons, but probably the most important one is that a revolution is ongoing which has changed and will continue to change the role of phase 1 studies in drug development considerably.

Thus, the TAT Congress (“The Home of Phase 1 Oncology”) is no longer the exclusive domain of highly-specialized phase 1 investigators and their translational research scientists. It has become an event of prime interest to a much broader population. It is also the place for industry’s drug development specialists – from pharma and biotech – to discuss with the academic phase 1 community how the path to initial regulatory approval may be shortened and for regulators to see what is coming their way, often already in the near future, not 8 to 10 years down the road like in the old days.

First-in-human phase 1 studies have historically been “human toxicology” studies aimed at describing the drug’s toxicity, establishing the MTD, a recommended dose for phase 2 studies and, in several cases, describing the pharmacokinetics of the new drug.

In their Editorial “Phase I trials in oncology: a new era has started” (Ann Oncol 2015;26:7-9), Postel-Vinay and Soria have made it clear that the role of early-phase trials in oncology drug development has changed due to:

The advent of precision medicine and molecular targeted agents

Trial enrichment and increased response rates

Immuno-stimulatory antibodies

Open attitude of regulators (breakthrough designation and conditional approval)

Safety/toxicity is no longer the only focus of phase 1 studies. The goals and the design of phase 1 studies have changed. Their focus has broadened and now includes clinical activity/response and biomarker research in addition to safety. Molecular enrichment of the patient population has become a common feature of phase 1 studies.

This new phase 1 paradigm has already led to rapid (conditional) approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies with only a few hundred patients: e.g., crizotinib, ceritinib, nivolumab, pembrolizumab, and atezolizumab. Oncology phase 1 studies are no longer a necessary hurdle on the way to pivotal phase 3 trials, they themselves can provide sufficient evidence of antitumor efficacy for regulatory approval.This new role of phase I trials is currently debated by regulatory agencies, such as the FDA, which has tried to provide some

Registration Needs updating Register Now


Registration Cost
Early Registration

Late Registration From: 2017-02-04 To: 0--
On site Registration
Academic/Non Profit

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts


Marriott Rive Gauche Hotel & Conference Center

17 Boulevard Saint Jacques · Paris, 75014 France

Scientific Content Up to Date
Submission Info
Sponsors Exhibitors
General Info

Maureen de Graauw , Congress by design

Phone: 011-31-8-8089-8101


Organising Agency

Maureen de Graauw , Congress by design

Phone: 011-31-8-8089-8101


Official Event Webpage
Event map
Revelant Events